A
Annovis Bio, Inc. (ANVS)
NYQ – Real vaqt narxi. Valyuta: USD
2.28
-0.11 (-4.60%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NYQ – Real vaqt narxi. Valyuta: USD
2.28
-0.11 (-4.60%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Annovis Bio, Inc., klinik bosqichdagi dori platformasi kompaniyasi, Qo'shma Shtatlarda neyrodegeneratsiyani davolash uchun dorilarni ishlab chiqadi. Kompaniyaning yetakchi mahsulot nomzodi Buntanetap bo'lib, u Altsgeymer kasalligini davolash uchun 3-bosqichda, shuningdek, Parkinson kasalligini davolash uchun ochiq-label 3-bosqichda. U, shuningdek, miya jarohatlari va/yoki insultni davolash uchun 2 va 3-bosqich klinik sinovlarida bo'lgan ANVS405; va Altsgeymer kasalligi va demensiyaning keyingi bosqichlarida kognitiv qobiliyatni oshirish uchun ishlab chiqilgan 1-bosqich klinik sinovini yakunlagan ANVS301ni ishlab chiqadi. Annovis Bio, Inc. 2008 yilda tashkil etilgan va shtab-kvartirasi Malvern, Pensilvaniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Cheng Fang Ph.D. | Senior Vice President of Research & Development |
| Dr. Maria L. Maccecchini Ph.D. | Founder, Acting CFO, CEO, President & Executive Director |
| Mr. Blake Jensen M.B.A. | Head of Quality |
| Ms. Eve M. Damiano M.S., RAC | Senior Vice President of Regulatory Operations |
| Ms. Hilda Maibach | Senior Vice President of Statistics |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-04-30 | DEF 14A | tm261540-3_def14a.htm |
| 2026-04-10 | 8-K | tm2611267d2_8k.htm |
| 2026-03-25 | 8-K | tm269828d1_8k.htm |
| 2026-03-16 | 8-K | tm268976d1_8k.htm |
| 2026-03-13 | 10-K | anvs-20251231x10k.htm |
| 2026-02-12 | 8-K | tm266101d1_8k.htm |
| 2026-01-28 | 8-K | tm264292d1_8k.htm |
| 2025-11-13 | 8-K | anvs-20251112x8k.htm |
| 2025-11-12 | 10-Q | anvs-20250930x10q.htm |
| 2025-10-28 | 8-K | tm2529544d2_8k.htm |